Access, Guidelines, and the Gap in Personalized Medicine w/ Dr. Federico Monzon

What does personalized medicine really mean—and why does it remain so difficult to implement at scale?In this episode, Perry is joined by longtime colleague and molecular pathology expert Dr. Frederico Monzon for an in-depth conversation on the realities behind personalized medicine. Drawing from his experience across academia, clinical practice, and industry, Frederico reframes personalized medicine as not only identifying the right treatment—but also avoiding therapies that offer no benefit and may cause harm.In this episode, you’ll hear about:How personalized medicine has long existed in pathology, even before the term became a buzzwordWhy avoiding ineffective treatments is just as critical as finding the right oneThe ongoing challenge of access to diagnostic testing and actionable informationWhy many patients still aren’t tested—even when guidelines and coverage existThe role of clinical guidelines as guardrails, not rigid rulesTensions and opportunities between laboratories, insurers, and lab benefit managersHow unmet clinical need drives meaningful innovation in diagnosticsWhy collaboration across industry, academia, and payers is essentialWhat excites Frederico most about the future: multimodal medicine combining genomics, pathology, imaging, clinical data, and AIThe conversation closes with a forward-looking discussion on how breaking down data silos—and using AI responsibly—could help healthcare teams deliver more precise, cost-effective care tailored to each individual patient.—-------Stay connected with our host, Perry Dimas, here on LinkedIn!  📧 Interested in joining our medical director advisory group? Email us at [email protected] 🔗 Connect on LinkedIn: linkedin.com/company/accessdx